Evidence map›Paper›PMID 40904452›Full record

ReviewFrontiers in immunology2025

Molecular ingredients of an immunogen for long-lasting IgG.

Sneh Lata Gupta, Alexander R Meyer, Erika Kay-Tsumagari, Wei Cheng

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sneh Lata GuptaDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, United States.
Alexander R MeyerDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, United States.
Erika Kay-TsumagariDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, United States.
Wei ChengDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, United States.

Funding

Mechanisms of B Cell Responses to Particulate AntigensR01AI155653 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHENG, WEI, ZIKHERMAN, JULIE · 2021 to 2025
$3.6M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
NIAID NIH HHS R01 AI155653NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

The durability of vaccine-induced protection is a critical parameter in assessing the overall quality and long-term effectiveness of a vaccine. While the lifelong immunity conferred by certain vaccines is well recognized, the molecular components that underpin such long-lasting protection remain poorly understood. This knowledge gap is further complicated by the frequent inclusion of adjuvant formulations in licensed vaccines, the mechanisms of which are often multifaceted and not fully elucidated. In this review, drawing upon the portfolio of FDA-approved antiviral vaccines and incorporating insights from our own published studies in rodents, we propose that a virus-like structure - devoid of any engineered adjuvants - is all that is needed for a long-lasting IgG response in both mice and humans. This structure comprises two essential features: (1) the oriented display of viral surface protein antigens on a virus-sized scaffold, and (2) internal nucleic acids with native phosphodiester backbones. In fact, several inactivated virus vaccines that conform to this architecture have demonstrated effective and durable protection in human populations without the need for engineered adjuvants. Clarifying these structural and molecular determinants of viral immunogenicity may reduce the empirical nature of vaccine development, enable the rational design of next-generation self-adjuvanting antiviral vaccines, and inspire novel applications in noncommunicable diseases.

Indexed as

Antibodies, ViralImmunoglobulin GViral VaccinesAdjuvants, ImmunologicAnimalsAntigens, ViralHumansImmunogenicity, VaccineMiceAdjuvants, ImmunologicAntibodies, ViralAntigens, ViralImmunoglobulin GViral VaccinesantibodydurabilityIgGpersistencevaccinevirus

Identifiers

PMID40904452
PMCPMC12401933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.